Holen Sie sich die Stockscreener-App
991.87
0.53%
-5.72
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$997.59
Offen:
$1002.84
24-Stunden-Volumen:
1.33M
Relative Volume:
0.36
Marktkapitalisierung:
$886.98B
Einnahmen:
$59.42B
Nettoeinkommen (Verlust:
$18.41B
KGV:
49.05
EPS:
20.2197
Netto-Cashflow:
$6.44B
1W Leistung:
-5.14%
1M Leistung:
+7.35%
6M Leistung:
+28.25%
1J Leistung:
+23.49%
1-Tages-Spanne:
$990.46
$1,012.00
1-Wochen-Bereich:
$988.88
$1,051.48
52-Wochen-Spanne:
$623.78
$1,111.99
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
991.02 | 892.86B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
201.63 | 485.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.38 | 394.34B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.09 | 249.77B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
97.09 | 245.55B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-10 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
New Dividend ETF Launches Just As Fed Decision Looms — Is KDVD The SMID-Cap Play Investors Need? - Benzinga
Nobel Prize-Winning Chemist Carolyn Bertozzi Rejoins Eli Lilly’s (LLY) Board of Directors - TipRanks
Eli Lilly's (LLY) Orforglipron Compared to Pfizer's New Collaboration - GuruFocus
Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025 - Oncodaily
Eli Lilly (LLY) Completes Acquisition of Adverum Biotechnologies - GuruFocus
Looking At Eli Lilly's Recent Unusual Options Activity - Benzinga
Eli Lilly's Flying Tigers Acquisition Completes Tender Offer for Adverum Shares - marketscreener.com
Eli Lilly Moves Forward With Acquisition Of Adverum Biotechnologies - Nasdaq
Eli Lilly completes acquisition of Adverum Biotechnologies - Seeking Alpha
Lilly completes tender offer for Adverum Biotechnologies - Investing.com
Adverum Biotechnologies Stock (ADVM) Opinions on Lilly Acquisition - Quiver Quantitative
Eli Lilly (LLY) Achieves Key Milestone with Jaypirca in Phase 3 Trial - GuruFocus
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
How Lilly uses Big Pharma heft to lift up-and-coming biotechs - PharmaVoice
Eli Lilly and Company $LLY Shares Sold by Investment Management Corp of Ontario - MarketBeat
Eli Lilly's (LLY) Pirtobrutinib Shows Promising Results in Phase 3 Trial for CLL/SLL - GuruFocus
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition - Yahoo Finance
Lilly’s Jaypirca reduces progression risk by 80% in untreated CLL - Investing.com
Lilly's Jaypirca succeeds in late-stage trial as a first-line option in lymphoma - Seeking Alpha
State Street Corp Purchases 69,018 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly's stock drops as it slashes the price of Zepbound: Time to buy the dip? - MSN
Eli Lilly will be ‘aggressive’ in spending GLP-1 money, top dealmaker Van Naarden says - Endpoints News
The 2025 Weight-Loss Drug Gold Rush: How Eli Lilly Pulled Ahead, Novo Hit A Snag — And A Swarm Of Biotech Underdogs Are Closing In - Stocktwits
Daiwa Securities Group Inc. Cuts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Fayez Sarofim & Co Sells 17,947 Shares of Eli Lilly and Company $LLY - MarketBeat
Axa S.A. Decreases Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Shares Navigate a Contradictory Market Phase - AD HOC NEWS
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Sen. John Boozman - MarketBeat
Carolyn Bertozzi returns to Eli Lilly board of directors - Medical Dialogues
8-Day Sell-Off Sends Eli Lilly Stock Down 10% - Trefis
Lilly Adopts ABL Bio's ‘BBB Shuttle’ to Tackle Alzheimer’s Treatment Challenges - Businesskorea
Eli Lilly (LLY): Reassessing Valuation After a Sharp Three-Month Rally and Brief Pullback - simplywall.st
Eli Lilly (LLY) Raises Dividend by 15% - TipRanks
Eli Lilly (LLY) Boosts Dividend by 15.3% - GuruFocus
Eli Lilly’s Mounjaro joins China’s health insurance scheme, challenging competitors - WISH-TV
Meds from Pfizer, Lilly, J&J and more secure spots in China's 1st private insurance formulary - Fierce Pharma
Eli Lilly declares Q1 2026 dividend of $1.73 per share - marketscreener.com
Lilly declares first-quarter 2026 dividend - Investing News Network
Eli Lilly's Mounjaro added to China's state insurance list for diabetes treatment - Reuters
Eli Lilly Raises Quarterly Dividend to $1.73 a Share From $1.50, Payable March 10 to Shareholders of Record on Feb. 13 - marketscreener.com
Eli Lilly's (LLY) Orforglipron Benchmark Surpassed by Competitor in Weight Loss Study - GuruFocus
Lilly declares first quarter 2026 dividend of $1.73 per share By Investing.com - Investing.com UK
Eli Lilly & Co. (LLY) Declares $1.73 Quarterly Dividend; 0.7% Yield - StreetInsider
Eli Lilly's Leukemia Drug Matches Johnson & Johnson's Imbruvica In Untreated Patients - Benzinga
Guggenheim maintains buy on Eli Lilly (LLY) after "another impressive year" - MSN
Guggenheim Maintains Buy on Eli Lilly (LLY) After “Another Impressive Year” - Insider Monkey
Guggenheim Maintains Buy on Eli Lilly (LLY) After "Another Impressive Year" - Finviz
With weight loss windfall, Lilly looks to become ‘backbone’ of global innovation: exec - Fierce Biotech
Eli Lilly's (LLY) Orforglipron Faces New Competition with GPCR's Clinical Data - GuruFocus
Carolyn Bertozzi returns to Lilly board of directors - marketscreener.com
Carolyn Bertozzi to Rejoin Eli Lilly (LLY) Board in December 202 - GuruFocus
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.01%
1.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):